Erector Spinae Plane Block Versus Conventional Analgesia in Complex Spine Surgery

• Status: Enrolling by invitation
• Trial end date: 2023-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Enhanced recovery pathways (ERPs) emphasize evidence-based, multimodal anesthetic and analgesic choices to minimize opioid consumption while providing adequate pain control after surgery. Although ERPs for spine surgery are now being described, few pathways include regional analgesia. The Erector Spinae Plane Block (ESPB) may represent a novel opportunity to incorporate regional analgesia into ERPs for spine surgery. To date, there is minimal data to support the utility of ESPB in spine surgery, and this block has not yet been evaluated in complex spine surgery.

This study seeks to see whether ESPB will reduce opioid consumption and pain scores, and improve patient recovery during the first 24 hours after complex spine surgery when included in a comprehensive ERP.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital for Special Surgery, New York
• Treatments: BB 1101; Bupivacaine; Dexamethasone; Dexamethasone acetate

Criteria

Inclusion Criteria:

• Age 18-80

• Planned primary complex spine surgery: >2 level- lumbar and/or thoraco-lumbar spine fusion with or without decompression

• Planned stand-alone posterior surgical approach

• Able to follow study protocol

• Able to communicate in English (outcome questionnaires validated in English)

Exclusion Criteria:

• Age <18 or >80

• Revision surgery

• BMI > 35

• planned prolonged intubation/intubation overnight on night of surgery

• Unable to communicate in English

• History of chronic pain condition requiring gabapentin/pregabalin/antidepressant medication longer than 3 months

• Opioid tolerance (>60 OME daily for >2 weeks)

• Allergy, intolerance or contraindication to any protocol component/study medication/technique

• Patient refusal of regional analgesia (ESPB)